Summit Therapeutics SMMT Unrealized Gain (Loss), Foreign Currency Transaction, before Tax
Unrealized Gain (Loss), Foreign Currency Transaction, before Tax at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ForeignCurrencyTransactionGainLossUnrealized.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's unrealized gain (loss), foreign currency transaction, before tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's unrealized gain (loss), foreign currency transaction, before tax?
- Summit Therapeutics (SMMT) reported unrealized gain (loss), foreign currency transaction, before tax of -$190K in Q1 2026.
- How has Summit Therapeutics's unrealized gain (loss), foreign currency transaction, before tax changed year-over-year?
- Summit Therapeutics's unrealized gain (loss), foreign currency transaction, before tax decreased by 184.8% year-over-year, from $224K to -$190K.
- What does unrealized gain (loss), foreign currency transaction, before tax mean?
- Non-cash gains or losses caused by changes in exchange rates on foreign currency holdings.
- How do you interpret unrealized gain (loss), foreign currency transaction, before tax?
- High volatility indicates significant exposure to foreign currency fluctuations in international operations.
- How does unrealized gain (loss), foreign currency transaction, before tax compare across companies?
- Common for multinational corporations with operations in multiple jurisdictions.